321 HARRISON AVENUE, BOSTON, MA
Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Election of Directors - Thomas Civik, Freda Lewis-Hall, and Michael Metzger
Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Annual Report to Security Holders
Amended material disclosure
Investor Presentation
Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus Filed Pursuant to Rule 424(b)(2)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities